University of Auckland Inventors Fund
VC Fund
University of Auckland Inventors Fund is a VC fund focused on Health Care and Biotechnology. University of Auckland Inventors Fund
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries University of Auckland Inventors Fund invests in
Stages University of Auckland Inventors Fund invests in
Countries University of Auckland Inventors Fund invests in
Round sizes
Round size
- Seed
- $2.2M–$2.5M
- Pre-Seed
- $337k–$972k
- Series A
- $1.4M–$18M
Investment Focus
Industry
- Health Care 4 (44%)
- Biotechnology 4 (44%)
- Therapeutics 2 (22%)
- Health Diagnostics 2 (22%)
- Audio 1 (11%)
Stage
- Seed 2 (22%)
- Pre-Seed 2 (22%)
- Series A 2 (22%)
- Series B 1 (11%)
- Convertible Note 1 (11%)
Country
- New Zealand 8 (89%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Luminoma
|
Luminoma is a medical device manufacturer that offers LumAssure, a device that indicates whether a skin lesion is malignant or benign. | $2.5M / Seed / Jan 01, 2024 | |
TamoRx
|
TamoRx’s founding inventors have discovered a novel biological mechanism within cells that restricts the immune system from fighting cancer. The research team is focused on developing a new therapy that frees patients’ immune systems from this restriction to increase immune attack on cancer cells within tumours offering a new hope for a broad rangeof cancer patients. TamoRx aims to develop small molecule inhibitors that work both as a single agent and in combination with other treatments, increasing the applicability of immunotherapy for patients. | $9.9M / Venture - Series Unknown / Jun 06, 2022 | |
Opo Bio
|
Opo Bio develops cell lines for the cultivated meat industry and researchers.They are building a multi-species and multi-cell type product bank for research and commercial usage. They are creating infrastructure that will enable the industry to progress and more effectively scale. | $971.8K / Pre-Seed / Jun 01, 2022 | |
RosterLab
|
RosterLab goal is to automate every part of the rostering process for healthcare. | $336.8K / Pre-Seed / Dec 17, 2021 | |
PowerON
|
Dielectric Elastomers for Soft Robotics | $2.2M / Seed / Sep 10, 2021 | |
Soul Machines
|
Founded in 2016, Soul Machines is a pioneer in the humanization of AI. We use our ground-breaking Biological AI technology to create engaging, empathetic AI Assistants, powered by our patented Digital Brain™. Our revolutionary Soul Machines Studio tools allow anyone to reimagine customer engagement, drive deep interactivity, and create personalizeddigital experiences. Soul Machines is unique in delivering the full capabilities of human and machine collaboration in an ethical, responsive, and unprecedented way. | $57.5M / Series B / Jan 10, 2020 | |
Rain Oncology
|
Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technologyidentification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations. | $18.4M / Series A / May 21, 2018 | |
Dotterel Technologies
|
Dotterel is a company based in Auckland, New Zealand that develops noise reduction and audio recording technology for UAVs. They have been providing award-winning solutions for the screen industry, security/defence and noise mapping since 2015.Their company provides technology that passively makes UAVs quieter in noise sensitive applicationsIt also separately allows aerial audio recording directly from the UAV in real-time. This technology opens the use of UAVs in applications and industries where use was previously impossible due to their noise.Being a Techstars company, they develop solutions in partnership with various Universities. Their partners include The University of Auckland, University of NSW, University of Sydney and M.I.T. | $336K / Convertible Note / Aug 01, 2017 | |
Upside Biotechnologies
|
Upside is developing the most advanced and best treatment for severe burns. The Upside product is a regenerative medicine solution to current shortcomings in the current treatment of severe burns patients. Upside will take a small sample of unburnt patient skin and grow it into differentiated, graftable skin in order to cover the patient’s ownburns. Product advantages are that Upside's engineered skin is produced faster than any competitive pipeline product, it is supplied in bigger sheets and has good handling characteristics. Upside has intellectual property covering the processes conferring these specific advantages. | $1.4M / Series A / Mar 21, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does University of Auckland Inventors Fund invest in?
University of Auckland Inventors Fund invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in New Zealand. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is University of Auckland Inventors Fund's check size?
University of Auckland Inventors Fund typically joins rounds of $2.2M–$2.5M at Seed, $337k–$972k at Pre-Seed and $1.4M–$18M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds University of Auckland Inventors Fund participates in.
When did University of Auckland Inventors Fund last invest?
The most recent investment recorded for University of Auckland Inventors Fund closed in Jan 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
